Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies
about
Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysisAntiretroviral therapy uptake and coverage in four HIV community cohort studies in sub-Saharan AfricaEstimation and Short-Term Prediction of the Course of the HIV Epidemic Using Demographic and Health Survey Methodology-Like DataWhere to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?Using age-specific mortality of HIV infected persons to predict anti-retroviral treatment need: a comparative analysis of data from five African population-based cohort studies.Economic returns to investment in AIDS treatment in low and middle income countries.Improved data, methods and tools for the 2007 HIV and AIDS estimates and projections.A missing piece in the puzzle: HIV in mature adults in sub-Saharan AfricaThe potential impact and cost of focusing HIV prevention on young women and men: A modeling analysis in western Kenya.A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008Further benefits by early start of HIV treatment in low income countries: survival estimates of early versus deferred antiretroviral therapy.Population-level reduction in adult mortality after extension of free anti-retroviral therapy provision into rural areas in northern Malawi.HIV-infected former plasma donors in rural Central China: from infection to survival outcomes, 1985-2008.Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings.Scaling up towards international targets for AIDS, tuberculosis, and malaria: contribution of global fund-supported programs in 2011-2015.Long-term costs and health impact of continued global fund support for antiretroviral therapyAssociation of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults.Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making.Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.Why the proportion of transmission during early-stage HIV infection does not predict the long-term impact of treatment on HIV incidenceUnderstanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community.Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi.CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and SwitzerlandEstimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa.Antiretroviral treatment coverage in a rural district in Tanzania--a modeling study using empirical data.Modelling HIV epidemics in the antiretroviral era: the UNAIDS Estimation and Projection package 2009.Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapyNew indicators for delay in initiation of antiretroviral treatment: estimates for CameroonAccess to, and uptake of, antiretroviral therapy in a developing country with high HIV prevalence: a population-based cohort study in rural Uganda, 2004-2008CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time.Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South AfricaTuberculosis in Cape Town: An age-structured transmission model.Factors affecting timing of antiretroviral treatment initiation based on monitoring CD4 counts.Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV riskViral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis.Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realizedAntiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters.
P2860
Q28068815-E33EC667-731F-4FCF-8116-45AB58C78FCFQ28727780-C7E4C3EB-E672-4443-BA23-CF314030436CQ30000083-3C7693EF-1946-44F8-984B-445D7C742265Q30352591-61D48C97-E411-4AA0-8804-795D66141808Q30560888-49C1C269-B164-48EE-A0DD-C84832EE0F12Q31036894-7D838088-802A-4863-B3EE-C47D4C8E0917Q31164541-F3350F72-61C3-46BD-BA1D-F0F32DC0365EQ33353214-8B8D1C9F-0BA1-47D4-BE30-406E27D86089Q33558726-674517F2-B01B-47C9-B46D-1D5F7AC8E0BDQ33608640-E389A381-CDF2-4CE9-AE3D-7C44FE001ECBQ33718364-12EA8C2C-332E-4424-BD66-6B5957B6FE56Q33728235-DD16997C-7007-4A35-9D0E-98892A6A2AFEQ33742029-45ADA923-4AB7-4789-8C9C-89AABA6D1A98Q33780939-99704CD3-F6EE-4A04-BC94-69949B2CEB92Q33839300-FACAFA3B-43F4-4095-95D8-CA208327B89AQ33952153-F6B9D236-BE8A-4BF7-8E1A-703F4EF555E4Q33958103-DD335553-AE93-4A74-9D42-B722D4C66CC1Q34081339-44F9D243-2861-4998-B32B-B366178B80E1Q34339523-B44C2480-3078-4EBE-A4EA-7315B921D033Q34387168-954E2F12-EEBC-4BF1-ABFC-CCB56F9C3786Q34526461-17953318-E9D0-4F4E-95E3-E5E793D19A3CQ34571215-E840F549-7EA8-4344-885F-318CBB2D4300Q34647897-35FFDEDA-059C-4573-AE4D-160111178519Q34664047-51538461-CBEE-4508-9000-9B0C37928CE3Q35007321-D55B3ACA-6858-40D9-9068-A4EAFB8661DEQ35146412-775DD9E3-3536-4C49-B156-EC9C26E07220Q35214944-EF0C3CA8-37CB-4154-833B-6C9679FCD572Q35214949-ABCEA969-918F-415B-8429-5290351A5E20Q36089497-B0CB8E8A-F07C-4976-BDA5-6B70FFCBC010Q36236953-3B5859E7-B42A-4013-8913-1E0C6B1AB37CQ36282724-E47E8B89-FD08-4419-9123-B3770EF6EFE1Q36380146-935DD4F5-77EE-481D-95DA-54E9404846ADQ36686287-DFF73FFF-385C-4DCA-B9FF-5A0DA1F95994Q36831346-A70E2F95-A7DE-4445-A7CD-FD7BF7C32F91Q36888158-81E3973B-9F92-4441-BD28-C10E1A68922DQ37112617-AB41D58A-A3C0-42A7-B8C4-31B354EB60ACQ37298218-5BC256CE-0A24-4819-8DD0-3142DE65EB61Q37393668-D315DFAD-37B9-4546-9422-C2B3E3F4ED19Q37494332-29CE3FCA-769B-4A7B-B7F5-C4BE87457239Q37578944-899C82A2-0B52-43A6-97FF-AE16779BAA52
P2860
Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Duration from seroconversion t ...... nalysis of prospective studies
@en
type
label
Duration from seroconversion t ...... nalysis of prospective studies
@en
prefLabel
Duration from seroconversion t ...... nalysis of prospective studies
@en
P2093
P2860
P921
P356
P1476
Duration from seroconversion t ...... nalysis of prospective studies
@en
P2093
Albert Minga
Anthony Ndyanabo
Caroline Costello
Charlotte Lewden
Kenrad E Nelson
Lieve Van der Paal
Marcel Zwahlen
Matthias Egger
Ram Rangsin
Simon Wandel
P2860
P304
P356
10.1136/STI.2008.029793
P478
84 Suppl 1
P577
2008-08-01T00:00:00Z